Received Apr 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | az2a3 | — |
patient missed her second dose of Twinrix at one month and received the second dose late; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 39-year-old female patient who received HAB (Twinrix) (batch number az2a3, expiry date 05-FEB-2028) for prophylaxis. Previously administered products included Twinrix (1st dose received on 18-SEP-2025 with batch number 324BY and expiry date 28-SEP-2026). On 23-APR-2026, the patient received the 2nd dose of Twinrix. On 23-APR-2026, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: patient missed her second dose of Twinrix at one month and received the second dose late). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 23-APR-2026 The patient received the second dose of Twinrix late.